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Abstract
Background: Selenite is a promising anticancer agent which has been shown to induce apoptosis
in malignant mesothelioma cells in a phenotype-dependent manner, where cells of the
chemoresistant sarcomatoid phenotype are more sensitive.
Methods: In this paper, we investigate the apoptosis signalling mechanisms in sarcomatoid and
epithelioid mesothelioma cells after selenite treatment. Apoptosis was measured with the Annexin-
PI assay. The mitochondrial membrane potential, the expression of Bax, Bcl-XL, and the activation
of caspase-3 were assayed with flow cytometry and a cytokeratin 18 cleavage assay. Signalling
through JNK, p38, p53, and cathepsins B, D, and E was investigated with chemical inhibitors.
Furthermore, the expression, nuclear translocation and DNA-binding activity of p53 was
investigated using ICC, EMSA and the monitoring of p21 expression as a downstream event. Levels
of thioredoxin (Trx) were measured by ELISA.
Results: In both cell lines, 10 μM selenite caused apoptosis and a marked loss of mitochondrial
membrane potential. Bax was up-regulated only in the sarcomatoid cell line, while the epithelioid
cell line down-regulated Bcl-XL and showed greater caspase-3 activation. Nuclear translocation of
p53 was seen in both cell lines, but very little p21 expression was induced. Chemical inhibition of
p53 did not protect the cells from apoptosis. p53 lost its DNA binding ability after selenite
treatment and was enriched in an inactive form. Levels of thioredoxin decreased after selenite
treatment. Chemical inhibition of MAP kinases and cathepsins showed that p38 and cathepsin B had
some mediatory effect while JNK had an anti-apoptotic role.
Conclusion: We delineate pathways of apoptosis signalling in response to selenite, showing
differences between epithelioid and sarcomatoid mesothelioma cells. These differences may partly
explain why sarcomatoid cells are more sensitive to selenite.
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Background
Selenite is a redox-modulating compound which is
increasingly investigated for use as an anticancer agent.
We have recently shown that selenite induces apoptosis in
malignant mesothelioma cells in a dose-, time- and phe-
notype-dependent manner, with a more potent effect on
sarcomatoid cells [1,2]. Promising anti-cancer effects have
also been shown in in vitro models of lung, prostate,
breast, skin, and hematologic cancers [3-12], with a selec-
tive effect upon malignant cells compared to normal cells
[1,4,13]. Several investigators have showed independ-
ently that selenite cytotoxicity can be inhibited by antioxi-
dants [1,14-19]. Redox regulation is likely to influence
cellular sensitivity to selenite, and we have reported that
selenite decreases the activity of thioredoxin reductase
(TrxR) [1]. Together with thioredoxin (Trx) and NADPH,
it forms the thioredoxin system, which is highly active in
redox signalling and defence against oxidative stress.
Malignant mesothelioma is a tumor of the serosal mem-
branes, most often arising in the pleura after prolonged
asbestos exposure. This tumor has a peculiar pattern of
differentiation, where the malignant cells may assume
either an epithelioid or a sarcomatoid phenotype. These
two phenotypes exhibit differences in their biological
behavior, as evidenced by gene expression analyses [20-
23] and the fact that presence of sarcomatoid cells is asso-
ciated to poor prognosis and increased therapy resistance
[24-26]. The median survival time from diagnosis is
around 12 months [27]. Response rates to current phar-
macological therapies are low, reaching only 40% at best
[28,29].
This study aimed to investigate apoptosis signalling dur-
ing selenite treatment in an epithelioid and a sarcomatoid
mesothelioma cell line. Both were initially derived from
the same tumor [30], and the latter is more sensitive to
selenite. Thus, we anticipated the emergence of differ-
ences in apoptosis signalling in response to selenite that
might explain the differential sensitivity of the two cell
lines.
Methods
Cells and culture
This study was carried out using a well-established model
system for mesothelioma differentiation, consisting of the
two cell sub-lines STAV-AB and STAV-FCS. Cells were
derived from a single tumor, and subsequently induced to
differentiate into the epithelioid (STAV-AB) and the sarco-
matoid phenotype (STAV-FCS), respectively, by altering
the serum composition [30]. Hence, STAV-AB cells were
grown in Gibco RPMI 1640 medium (Invitrogen) and
10% human AB serum, whereas STAV-FCS cells were
grown in the same medium and 10% fetal calf serum. The
specific differentiation of these cells has been evidenced
by immunoprofiling showing that STAV-AB cells express
more cytokeratin, whereas STAV-FCS cells have stronger
reactivity to vimentin antibodies [21] as well as by mor-
phometry. The elongated sarcomatoid cell morphology of
the STAV-FCS cells and the more round epithelioid mor-
phology of the STAV-AB cells have been confirmed by
average length:width ratios of 3.42 in the STAV-FCS cells
and 1.58 in the STAV-AB cells [31]. Jurkat cells were
obtained from the American Type Culture Collection
(ATCC) and grown in RPMI 1640 medium and 20% fetal
calf serum. All cells were grown at 37°C with 5% CO2 and
passaged approximately twice per week.
Treatment of cell cultures and inhibition of signalling 
enzymes
To investigate the contributions of several signalling path-
ways, inhibitors were used against key enzymes. Cells
were washed, trypsinized and re-seeded with the respec-
tive inhibitors (specified in table 1) 24 h prior to selenite
treatment, except for the JNK-inhibitor, with which they
were pre-incubated for 1 h. Selenite was then added to the
medium and the cells were harvested 24 or 48 h later.
Titrations were performed with all inhibitors based on the
manufacturers' instructions and concentrations reported
in the literature. In all cases, the highest non-toxic doses
tested were accepted.
Cell viability assays
Viability assays were performed in conjunction with flow
cytometry experiments to obtain internal controls. Aliq-
uots of cell suspensions prepared for flow cytometry were
plated in triplicates in 96-well plates, with a density of
Table 1: Chemical inhibitors against apoptosis signalling enzymes
Inhibitor Target Concentration Purchased from
SB 203580 p38 5 μMM e r c k
SP 600125 JNK 10 μM A.G. Scientific
Pifithrin p53 10 μM A.G. Scientific
Pepstatin A Cathepsin D, E 5 μMC a l b i o c h e m
Ca-074 Me Cathepsin B 10 μM SERVA Electrophoresis GmbHJournal of Experimental & Clinical Cancer Research 2009, 28:92 http://www.jeccr.com/content/28/1/92
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approx. 5000 cells per well. They were then analysed using
the WST-1 assay (Roche), whereby a tetrazolium salt is
cleaved by mitochondrial enzymes to yield a coloured
product, to measure viability. The plates were read in a
Spectramax spectrophotometer at 450 nm with subtrac-
tion of background absorbance at 600 nm.
Flow cytometric analyses
Flow cytometric assays for detection of apoptosis were car-
ried out using the Annexin V kit (Caltag Laboratories)
according to the manufacturer's protocol. Briefly,
trypsinized cells were resuspended in Binding Buffer with
Annexin V-FITC and Propidium Iodide (PI), and incu-
bated for 15 minutes in the dark.
For analysis of Bax expression, cells were fixed in 0.25%
paraformaldehyde, and permeabilised with 100 μg/ml
Digitonin. Aliquots were then incubated for 30 minutes
with phycoerythrin-conjugated mouse anti-human Bax
antibody (Santa Cruz, sc20067) or mouse IgG as a con-
trol, both in final dilution 1:10. Morphological controls
were established using cytospins. Slides were fixed in 4%
buffered formaline, washed 2 × 5 min in PBS, and air-
dried. Staining was performed with the same antibody
concentration and incubation time, and the staining was
evaluated by confocal microscopy.
For analysis of Bcl-XL expression, cells were fixed in 1%
formaldehyde, and permeabilised with 0.1% Saponin.
Aliquots were then incubated for 15 minutes with phyco-
erythrin-conjugated rabbit anti-human Bcl-XL antibody
(GeneTex, GTX46035), final dilution 1:800, or rabbit IgG
as a control. The secondary antibody Alexa 488 goat anti-
rabbit IgG was diluted 1:1600, and incubation was per-
formed for 15 minutes in the dark.
The mitochondrial membrane potential was measured
using two independent methods. 1) The Mitochondria
Staining Kit (Sigma) was used according to the manufac-
turer's instructions. Briefly, cells were trypsinised and then
resuspended in a solution of 45% medium, 5% serum and
50% staining solution containing the JC-1 probe. They
were incubated for 20 min in 37°C, and then washed with
staining buffer. Cells treated with Valinomycin were used
as a positive control. 2) With the fluorescent probe
DiOC6(3) (3,3-dihexyloxacarbocyanine iodide; Molecu-
lar Probes), cells were incubated for 15 minutes with con-
centrations ranging from 1 to 100 nM DiOC6(3). After
staining, an aliquot of cells was prepared for confocal
microscopy to verify that the staining was localized to the
mitochondria.
For analysis of procaspase-3 expression, cells were fixed in
1% paraformaldehyde, and permeabilised with 10 μg/ml
Digitonin. Aliquots were then incubated for 30 minutes
with a rabbit monoclonal antibody to procaspase-3
(Abcam, ab32150), final dilution 1:150, or rabbit IgG as
a control. The secondary antibody Goat anti-Rabbit IgG-
FITC (Abcam, ab6717) was diluted 1:300, and incubation
was performed for 30 minutes in the dark.
Detection of the active form of caspase-3 was performed
with a FITC-conjugated antibody (BD Biosciences,
559341). Cells were fixed in 1% paraformaldehyde, and
resuspended in 100 μg/ml Digitonin solution with anti-
body in final dilution 3:20, and incubated for 30 minutes
at 4°C. Cells treated with 2 μM doxorubicin for 24 h were
used as positive controls.
Flow cytometry was always performed immediately after
the staining was completed. All analyses were performed
on a Becton Dickinson flow cytometer and the data were
processed in the Cell Quest program.
Cytokeratin 18 cleavage assay
The M-30 Apoptosense assay (Peviva, Stockholm) meas-
ures cytokeratin 18 fragments specifically produced by
cleavage by caspases 3, 6, 7, and 9 [32,33]. Cells were
seeded in 96-well microtiter plates with or without 10 μM
selenite and 0.2 μg/ml doxorubicin. After 24 h, cells were
lysed by the addition of 10 μl 10% Tergitol-type NP-40
(Sigma-Aldrich) to each well. The ELISA analysis was car-
ried out according to the manufacturer's instructions.
Briefly, 25 μl samples were incubated together with 75 μl
horseradish peroxidase-conjugate solution on the ELISA
microplate for 4 h on a shaker. 200 μl of tetramethylben-
zidine substrate solution were added and the plate was
incubated for a further 20 min. The reaction was stopped
by the addition of 50 μl 1.0 M H2SO4, and the absorbance
at 450 nm was determined on a Spectramax spectropho-
tometer.
Immunocytochemistry and confocal microscopy
For analysis of nuclear translocation of p53 and p21, cyt-
ospins were prepared. For p53 analysis, the slides were
fixed in ice-cold dry acetone. Prior to staining, they were
heated to 100°C for 5 min in citrate buffer, pH 6.0. Stain-
ing was performed using the p53 Refine kit (Novacastra).
For p21 analysis, the slides were fixed in 4% buffered for-
maline, and air-dried. Staining was performed with a
mouse monoclonal antibody (Calbiochem, OP64),
diluted 1:200, for 30 minutes.
For analysis with monodansyl cadaverine (MDC), cells
were grown on sterilised Superfrost Plus slides (Menzel
GmbH &Co). The slides were stained for 10 minutes with
10 μM MDC (BioChemica), and immediately analysed by
confocal microscopy.Journal of Experimental & Clinical Cancer Research 2009, 28:92 http://www.jeccr.com/content/28/1/92
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DNA binding assay for p53
Nuclear extracts were prepared as described previously
[34]. Electrophoretic Mobility Shift Assay (EMSA) was
conducted using the LightShift Chemiluminescent EMSA
Kit (Pierce). 20 μg of nuclear protein was used for each
sample. The double-stranded oligonucleotide probes for
the p53 binding site (sense 5'-TACAGAACATGTCTAAG-
CATGCTGGGG-3') were annealed and labeled with
biotin. To label DNA probes, the Biotin 3' End DNA Labe-
ling Kit (Pierce) was used according to the manufacturer's
protocol.
Measurement of Thioredoxin
ELISA was used to quantify the amounts of thioredoxin
(Trx) in the cells. The assay was adapted from Pekkari et al
[35]. Wells were coated with a primary monoclonal anti-
body (2G11, kindly provided by dr. Anders Rosén of the
University of Linköping) overnight at 4°C, 5 μg/ml
diluted in carbonate buffer, pH 9.6. Secondary bioti-
nylated antibody (IMCO Corporation) was added in a
concentration of 5 μg/ml. Absorbance at 405 nm was
measured using a SpectraMax 250 spectrophotometer
(Molecular Devices). Data were analyzed using the SOFT-
max Pro software, v. 2.6.
Statistical methods
All experiments were performed at least three times. When
one representative experiment is shown, it was chosen on
the basis of being closest to the average of all the experi-
ments performed. Student's t-test, two-way ANOVA with
Dunnett's post test or Bonferroni's multiple comparison
test, and χ2-tests were used to determine statistical signifi-
cance. The choice of statistical method for each experi-
ment is indicated in the respective legend text.
Results and discussion
Selenite is a strong prooxidant when used in cytotoxic
doses, and may induce apoptosis. Many independent
researchers have confirmed that the cytotoxicity of
selenite is mediated by oxidative stress, in cell types so var-
ious as malignant mesothelioma [1], hepatoma
[14,15,36], cancers of the breast [16], prostate
[4,17,19,37], and uterine cervix [18], glioma [38], lym-
phoma [39], and Jurkat T-cells [40]. Cell death with apop-
totic characteristics has also been observed in erythrocytes
following selenite treatment [41]. Selenite-induced oxida-
tion may target many cellular components, and the result-
ing damage and cell signalling is therefore likely to be
dependent on the constitution of the cell in question, and
may vary between cell types, and indeed between mes-
othelioma cells of different phenotypes. This study is the
first to our knowledge to investigate whether such differ-
entiation-dependent variation accounts for differences in
sensitivity between cell phenotypes.
Selenite induced apoptosis and sarcomatoid cells were 
more sensitive
More than 90% of the untreated cells were viable, appear-
ing in the lower left quadrant. Representative Annexin-PI
plots are shown in figures 1A and 1B. Baseline early apop-
tosis (cells in the lower right quadrant), averaged over
three experiments, was 4% in the epithelioid cells (Figure
1C) and 9% in the sarcomatoid cells (Figure 1D). Note
that the figures 1A and 1B show only one representative
experiment. 10 μM selenite decreased the viable fraction
particularly in the sarcomatoid cells, as has also been
reported previously [1]. This finding was confirmed by
viability assays (data not shown). Selenite also increased
the proportion of early apoptotic cells (Figures 1C and
1D). There were around 15% of cells in the upper quad-
rants in both cell types after selenite treatment, represent-
ing cells late in their apoptotic process or undergoing
necrosis. A time-course experiment with measurements
up to 48 h was performed to verify that 24 h was a suitable
time-point for analysis (data not shown).
Loss of mitochondrial membrane potential (δΦm) is asso-
ciated with apoptosis. Following selenite treatment, a 3-
fold loss of δΦm was seen in both cell types (Table 2).
These findings were confirmed by DiOC6(3) staining, and
the specificity for mitochondria was verified using confo-
cal microscopy (data not shown). The loss of δΦm in both
phenotypes after selenite treatment agrees well with ear-
lier studies [15,19,36].
To further delineate the role of signalling molecules
among the MAP kinases and cathepsins, chemical inhibi-
tors against these enzymes were used (Table 1). In the
untreated epithelioid cells, the inhibitors decreased the
baseline apoptotic fraction by 20–50% [see Additional
file 1]. This demonstrates the efficacy of the inhibitors at
the concentrations in which they were used. None of the
enzyme inhibitors affected the proportion of viable cells
during Annexin-PI apoptosis assays, although the WST-1
viability assays indicated a modest growth inhibitory
effect of CA 074-Me and SB 203580 (data not shown).
Further controls to verify the efficacy of the chemical
inhibitors were obtained by testing them on Jurkat cells
over a 25 h time course following apoptosis induction
with 0,2 μM staurosporine. The inhibitors of JNK, p53
and cathepsin D and E successfully decreased the apopto-
sis induction, whereas the cathepsin B inhibitor increased
it [see Additional file 2].
p38 inhibition reduced apoptosis frequency slightly in 
sarcomatoid cells
In the sarcomatoid cells, the p38 inhibitor SB203580
caused a small decrease in the apoptotic response to
selenite (Figure 1D). In the epithelioid cells, p38 inhibi-Journal of Experimental & Clinical Cancer Research 2009, 28:92 http://www.jeccr.com/content/28/1/92
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tion had no effect on the ability of selenite to induce
apoptosis. However, selenite caused an even more marked
drop of the δΦm after p38 inhibition in both cell types
(Table 2). This indicates that p38 was involved in apop-
totic signalling particularly in the more sensitive sarcoma-
toid cells. The effect of inhibition was small however, and
it cannot be regarded a key pathway. Activation of p38
after selenite exposure has previously been shown in cer-
vix [18], leukemia [42] and prostate cancer cells [5].
Inhibition of JNK increased the apoptotic response of 
epithelioid cells
Inhibition of JNK increased the proportion of selenite-
induced early apoptotic cells by more than two thirds in
the epithelioid cells (Figure 1C). In the sarcomatoid cells
the effect was comparable to that without the inhibitor
(Figure 1D). Scant effect on the loss of δΦm was observed
(Table 2). JNK apparently played no role in apoptosis sig-
nalling in the sarcomatoid cells. In the epithelioid cells,
JNK even had a small antiapoptotic effect. The lack of
proapoptotic activity is concordant with earlier findings in
cervix cancer cells [18] but different from findings in pros-
tate cancer cells [5].
Selenite caused nuclear accumulation but inactivation of 
p53
Immunocytochemistry revealed that both epithelioid and
sarcomatoid cells responded to selenite with a time-
dependent increase of nuclear p53 immunoreactivity.
After 24 h, the proportion of positive cells was increased
approximately 1.5-fold (Figure 2A–E), and after 48 h,
approximately 2-fold (not shown). EMSA analysis
showed, however, that p53 exhibited less binding to DNA
after selenite treatment (Figure 3B). Thus, although
selenite caused nuclear accumulation of p53, it also
decreased the DNA-binding activity. This result was sur-
prising, as p53 has been implicated as a mediator of Figure 1
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Selenite-induced apoptosis as determined by the Annexin-PI  assay and effects of inhibition of apoptosis signalling enzymes Figure 1
Selenite-induced apoptosis as determined by the 
Annexin-PI assay and effects of inhibition of apopto-
sis signalling enzymes. A and B: Representative Annexin-
PI dot plots with typical distribution patterns and gating after 
24 h treatment. Cells in the lower left quadrant are viable, 
those in the lower right quadrant are early apoptotic, and 
those in the upper quadrants are late apoptotic or necrotic. 
Early apoptosis in epithelioid (C) and sarcomatoid cells (D) 
before and after exposure to selenite for 24 h. Three inde-
pendent experiments are shown. Two-way ANOVA with 
Dunnett's post test was performed to determine statistical 
significance between cells treated with selenite only and 
selenite with the respective inhibitors.Journal of Experimental & Clinical Cancer Research 2009, 28:92 http://www.jeccr.com/content/28/1/92
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selenite-induced apoptosis signalling in other cell systems
[5,17,18,43,44].
The expression of p21 (also known as Cip1 and WAF1) in
response to genotoxic stress is tightly regulated by p53
(reviewed in [45]), and we therefore measured it as an
additional indicator of p53 activity. The fraction of p21-
positive cells was approximately doubled by selenite treat-
ment (Figure 2F–J). Although these changes are statisti-
cally significant, the positive fraction was very small even
after selenite treatment. As a positive control, epithelioid
cells were treated with 2 μM doxorubicin and showed a
22% positive fraction (not shown).
Cells of either phenotype treated with the p53 inhibitor
Pifithrin did not show a decreased apoptosis frequency as
judged by Annexin-PI (Figure 1), nor a smaller loss of δΦm
(Table 2). This is particularly interesting since p53 inhibi-
tion decreased the baseline apoptosis in untreated cells
(Figure 1, Additional file 1). Consequently, p53 was active
in the control cells but was inactivated by selenite. Apop-
tosis was still induced by selenite, implicating p53-inde-
pendent pathways in this process.
To find the mechanism of inhibition, we considered the
complex regulation of p53 activity. The central DNA-
binding core domain of p53 contains one zinc atom. Zinc
chelators have been shown to cause accumulation of wild-
type p53 in a structurally aberrant form with inhibited
DNA-binding activity [46]. Selenium is a known chelator
of zinc and when applied in vivo as selenite or its reduced
form selenide, it forms nanocrystals of zinc-selenium with
free or loosely bound zinc [47]. Another possibility is that
selenite as an oxidizing agent may act directly upon regu-
latory cysteines on the p53 molecule, leading to an accu-
mulation of oxidized p53 incapable of DNA-binding [48].
Also, secondary mediated redox regulation needs to be
considered. The multifunctional protein Redox Effector
Factor 1 (Ref-1) is involved in the redox regulation of
stress inducible transcription factors such as Activating
Protein-1, Nuclear Factor-κB, Hypoxia Inducible Factor-1
and p53, and may play an important role in this system.
Ref-1 depends on thioredoxin (Trx) to maintain its active
reduced state [49-51]. In a yeast experimental system, it
has been shown that deletion of thioredoxin reductase
(TrxR) downregulates p53 activity by keeping it in its oxi-
dized form [52,53]. Trx overexpression on the other hand
has been shown to increase p53 transactivation of
reporter genes in human cell lines [49].
Protein levels of Trx were reduced by selenite treatment in
sarcomatoid cells, from 175 ng/mg to 100 ng/mg. The epi-
thelioid cells had a baseline expression of 57 ng/mg,
decreasing slightly to 52 ng/mg after selenite treatment
(Figure 3). It has been demonstrated previously that levels
of TrxR decrease significantly in both cell lines with
selenite treatment [1]. Consequently, redox inactivation
of p53 is a plausible explanation for the lack of activity
that was seen despite nuclear accumulation following
selenite exposure.
Selenite induced Bax up-regulation and Bcl-XL down-
regulation
The immunoreactivity for the proapoptotic mediator Bax
increased significantly in the sarcomatoid cells but not in
the epithelioid cells following selenite treatment (Figure
Table 2: Selenite-induced loss of mitochondrial membrane potential and effects of inhibition of apoptosis signalling enzymes
Epithelioid cells Sarcomatoid cells
Inhibitor Loss of δΦm after 
selenite treatmenta
Statistical 
significance vs. no 
seleniteb
Statistical 
significance vs. 
selenite onlyc
Loss of δΦm after 
selenite treatmenta
Statistical 
significance vs. no 
seleniteb
Statistical 
significance vs. 
selenite onlyc
Positive control 2.89 (± 0.68) 1.28 (± 0.18)
Selenite 3.41 (± 0.57) p < 0.01 3.30 (± 0.24) p < 0.001
JNK 0,94 (± 0.06) 1.05 (± 0.05)
JNK + selenite 3,96 (± 0.58) p < 0.001 ns 3.74 (± 0.25) p < 0.001 ns
p38 0.99 (± 0.04) 0.88 (± 0.03)
p38 + selenite 4.06 (± 0.63) p < 0.001 ns 4.15 (± 0.52) p < 0.001 ns
p53 0.74 (± 0.05) 0.92 (± 0.03)
p53 + selenite 2.62 (± 0.57) p < 0.05 ns 3.59 (± 0.52) p < 0.001 ns
Cathepsin B 1.27 (± 0.12) 1.46 (± 0.10)
Cathepsin B + 
selenite
5.68 (± 0.70) p < 0.001 ns 6.27 (± 0.75) p < 0.001 p < 0.01
Cathepsin D, E 0.93 (± 0.06) 0.90 (± 0.03)
Cathepsin D, E + 
selenite
3.95 (± 0.77) p < 0.001 ns 3.45 (± 0.37) p < 0.001 ns
a: Fold change in JC-1 green fluorescence. Range shows the standard error of the mean (SEM).
b: One-way ANOVA analyses were performed with Bonferroni's multiple comparisons test.
c: One-way ANOVA analyses were performed with Dunnett's post test. ns = not significant.Journal of Experimental & Clinical Cancer Research 2009, 28:92 http://www.jeccr.com/content/28/1/92
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4). This clear phenotypic difference may partially explain
why sarcomatoid cells are more sensitive to selenite. Mor-
phological controls verified that staining was localised to
cytoplasmic granules consistent with mitochondria (not
shown). Although activation of Bax in response to selenite
has been shown in other systems [9,17,18,44,54], this is
the first report of differential expression coupled to sensi-
tivity.
In mesothelioma, the antiapoptotic Bcl-2 family member
Bcl-XL is frequently overexpressed [55], and this has been
shown to be an important mechanism by which mesothe-
lioma cells gain apoptosis resistance [56]. In the epithe-
lioid cells, the Bcl-XL expression decreased markedly after
selenite treatment, whereas only a subpopulation of the
sarcomatoid cells showed lower expression after treat-
ment (Figure 4).
Selenite caused caspase activation particularly in the 
epithelioid cells
Both epithelioid and sarcomatoid cells showed a 6-fold
increase in caspase-mediated cleavage of cytokeratin 18
after selenite treatment (Figure 5), indicating activation of
caspases 3, 6, 7, and 9. Doxorubicin, as a positive control,
caused a 10-fold increase in the epithelioid cells and a 6-
fold increase in the sarcomatoid cells.
Nuclear translocation of p53 and p21 Figure 2
Nuclear translocation of p53 and p21. A-E: Immunocytochemical analysis of p53 performed on cytospin samples. A: Epi-
thelioid cells without selenite. B: Epithelioid cells treated with 10 μM selenite for 24 h. C: Sarcomatoid cells without selenite. 
D: Sarcomatoid cells treated with 10 μM selenite for 24 h. E: Fraction of cells with p53-positive nuclei after 24 h, as assessed by 
two independent observers. Bars show the 95% confidence interval. χ2-tests were employed. F-J: Immunocytochemical analysis 
of p21 performed on cytospin samples, as an additional readout for p53 activity. F: Epithelioid cells without selenite. G: Epithe-
lioid cells treated with 10 μM selenite for 24 h. H: Sarcomatoid cells without selenite. I: Sarcomatoid cells treated with 10 μM 
selenite for 24 h. J: Fraction of cells with p21-positive nuclei after 24 h, as assessed by three independent observers. Bars show 
the 95% confidence interval. χ2-tests were employed. Three independent experiments were performed.
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Flow cytometric analysis for procaspase-3 showed that
both cell types have a similar baseline expression. After
selenite treatment, subpopulations of both phenotypes
lose procaspase-3. In the epithelioid cells, this corre-
sponds to the appearance of a distinct subpopulation
(13%) that is positive for activated caspase-3. In the sarco-
matoid cells, there is also a small fraction (5%) of cells
that stain more intensely for activated caspase-3, but it is
not distinctly separated from the main peak (Figure 6).
Caspase-3 activation was confirmed in doxorubicin
treated-controls: 49% of epithelioid cells were positive,
and 20% of sarcomatoid cells (not shown).
Divergent data have been published regarding the role of
caspases in selenite-induced apoptosis. Several studies
have shown that selenite causes a caspase-independent
apoptotic cell death [6,18,40], whereas others have shown
caspase-dependence [9,17,36,57]. We report that caspase-
3 was activated in a sub-population of epithelioid cells,
but little reactivity was seen in sarcomatoid cells. The lim-
ited caspase activation in sarcomatoid cells was surprising.
A possible explanation could be an upregulation of Inhib-
itor of Apoptosis (IAP) family members such as survivin
and XIAP. Earlier studies have found that overexpression
Thioredoxin levels and p53 activity Figure 3
Thioredoxin levels and p53 activity. A: Amount of 
thioredoxin relative to total protein amount after 24 h. B: 
EMSA for p53 demonstrating less DNA-binding activity of 
p53 after selenite treatment in both cell types, but more 
markedly so in the epithelioid cells. Bars indicate the stand-
ard error of the mean. Student's t-test was performed. ns = 
not significant. Three independent experiments were per-
formed.
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Expression of Bax and Bcl-XL Figure 4
Expression of Bax and Bcl-XL. Top two panels: flow 
cytometric analyses of Bax expression. Sarcomatoid but not 
epithelioid cells responded to selenite treatment with a 
marked upregulation. Bottom four panels: flow cytometric 
analyses of Bcl-XL expression. Epithelioid cells lost Bcl-XL 
expression completely after selenite treatment, whereas sar-
comatoid cells showed a partial loss. Gray histograms show 
the negative controls for the immunostaining. Three inde-
pendent experiments were performed.
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of IAP family members is common in mesothelioma cells
[58-61].
Inhibition of cathepsin B but not of cathepsins D and E 
caused increased loss of δΦm
Cathepsins are a group of proteases that are physiologi-
cally present in lysosomes, and may be released upon
stimuli such as oxidative stress [62]. Cells that were pre-
treated with cathepsin B inhibitor CA-074 Me showed
slightly less apoptosis after selenite exposure (Figure 1). In
the sarcomatoid cells, this was reflected in correspond-
ingly increased viability. In the epithelioid cells, the viable
proportion decreased slightly instead. Interestingly, when
selenite was combined with the cathepsin B inhibitor, the
loss of δΦm was greater than with any other inhibitor
(Table 2). Cathepsin D and E inhibitor Pepstatin A did not
affect the induction of apoptosis by selenite, nor did it
alter the loss of δΦm.
Signs of autophagy were not detected
Autophagy is a form of programmed cell death in which
cells do not exhibit apoptotic characteristics. Kim et al
have shown that selenite induces autophagy in glioma
cells [38]. We wanted to investigate whether some of the
cell death that we observe could be due to autophagy.
Cells were stained with monodansyl cadaverine and ana-
lysed with confocal microscopy for the appearance of
granules that might represent autophagic vesicles. No
changes in the staining pattern could however be detected
between untreated and selenite-treated cells of either phe-
notype [see Additional file 3].
Concluding remarks
Our results clearly demonstrate that selenite causes a com-
plex pattern of cell death in malignant mesothelioma
cells. Selenite causes both apoptosis and necrosis, but cells
exhibiting apoptotic characteristics such as Annexin V
externalisation do not necessarily display other classical
apoptosis-related changes such as caspase-activation
[6,18,40]. It appears purposeful to consider selenite-
induced cell death to lie on a spectrum between apoptosis
Caspase activation as determined by cytokeratin 18 cleavage Figure 5
Caspase activation as determined by cytokeratin 18 
cleavage. M-30 Apoptosense assay showing the amounts of 
caspase-cleaved cytokeratin 18 fragments detected. Bars indi-
cate the standard error of the mean. For statistical analyses, 
two-way ANOVA with Dunnett's post test was used. Data 
represent the means of three independent experiments.
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and necrosis, where the exact mode of cell death differs
depending on phenotype characteristics.
Our results indicate that mesothelioma cells activate p38
and JNK in response to selenite, and that they accumulate
p53 in the nucleus, but in a form bereft of DNA-binding
activity. We hypothesise that this interesting phenome-
non is due to a shift in redox balance towards a prooxida-
tive state with increased levels of reactive oxygen species
(ROS) and a loss of thioredoxin system activity.
Sarcomatoid mesothelioma cells, although ordinarily
chemoresistant, are more sensitive to selenite than epithe-
lioid cells [1]. The differential activation of apoptosis-sig-
naling proteins on the level of the mitochondrion may
partially explain the observed differences in sensitivity.
A better understanding of the proapoptotic mechanisms
of selenite as well as of phenotype-dependent response
patterns in mesothelioma cells will aid the development
of cancer therapies with greater efficacy and which may be
better suited to the diverse biology of individual tumors.
Malignant mesothelioma is a heterogeneous entity, and
further studies on differentiation-related sensitivity to
selenite and other cytotoxic drugs are under way in our
laboratory using a panel of cell lines of varying epithe-
lioid-sarcomatoid differentiation.
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External verification of the efficacy of apoptosis signalling enzyme 
inhibitors. A-E: Apoptosis kinetics of Jurkat cells treated with stau-
rosporine and chemical inhibitors, to verify that the inhibitors were able 
to alter the apoptotic rate. Graphs show the proportion of early apoptotic 
cells as determined by flow cytometry. Numbers given on the graphs show 
the area under the respective curves. One experiment was performed.
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Monodansyl cadaverine staining for autophagy. A-D: Confocal micro-
graphs of cells stained with MDC. A: Epithelioid cells, untreated. B: Epi-
thelioid cells, treated with 10 μM selenite for 24 h. C: Sarcomatoid cells, 
untreated. D: Sarcomatoid cells, treated with 10 μM selenite for 24 h. In 
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autophagic vesicles. Bars are 50 μm. Three independent experiments were 
performed.
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Caspase-3 activation as determined by flow cytometry Figure 6
Caspase-3 activation as determined by flow cytome-
try. Top four panels: flow cytometric analyses of procaspase-
3. Sarcomatoid and epithelioid cells showed a similar baseline 
expression. In both cell types, a subpopulation lost expres-
sion after selenite treatment. Gray histograms show the neg-
ative controls for the immunostaining. Bottom four panels: 
flow cytometric analyses of caspase-3 activation. Selenite 
treatment caused the appearance of a distinctly positive sub-
population in the epithelioid cells, whereas the sarcomatoid 
cells showed a small positive subpopulation that was not dis-
tinctly separated from the main peak. Three independent 
experiments were performed. All eight panels are derived 
from the same experiment.Journal of Experimental & Clinical Cancer Research 2009, 28:92 http://www.jeccr.com/content/28/1/92
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